Peginterferon alfa-2a (Synonyms: Ro 25-8310/000) |
Catalog No.GC79378
One-Click Copy Product Info
|
Peginterferon alfa-2a (Ro 25-8310/000) is a 40 kDa branched pegylated IFN alfa-2a with antiviral and immunomodulatory activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 198153-51-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, Peginterferon alfa-2a (Ro 25-8310/000) (40 kDa; subcutaneous injection) extends the terminal elimination half-life to 15.0 h and the mean plasma residence time to 20.0 h in rats, and produces more sustained plasma exposure compared with conventional IFN alfa-2a[1]. Peginterferon alfa-2a (40 kDa) distributes to the liver and kidneys in rats. Intact Peginterferon alfa-2a remains detectable in the blood and liver for at least 24 h after administration, and exhibits reduced renal clearance and prolonged hepatic antiviral activity[1].
In Vitro, Peginterferon alfa-2a (Ro 25-8310/000) promotes the formation of ISGF3 by binding to Interferon Receptor on the surface of target cells, and induces the expression of antiviral effector proteins such as ISGs and Mx proteins, thereby exerting antiviral and immunomodulatory effects[2]
References:
[1]. Matthews SJ, et al. Peginterferon alfa-2a: a review of approved and investigational uses. Clinical therapeutics. 2004 Jul;26(7):991-1025.
[2]. Rajender Reddy K, et al. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Advanced drug delivery reviews. 2002 Jun 17;54(4):571-86.
| Cas No. | 198153-51-4 | SDF | |
| Synonyms | Ro 25-8310/000 | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)